Stephenson Cancer Center - Cancer Center Support Grant

总体：摘要 自2018年获得NCI称号以来，俄克拉荷马大学斯蒂芬森癌症中心(SCC) 作为一个组织，它继续成长和成熟。SCC的愿景是消除俄克拉荷马州和 Beyond通过其使命前进，提供以患者为中心、研究驱动的多学科癌症 关爱所有俄克拉荷马人。作为俄克拉荷马州唯一由NCI指定的癌症中心，SCC为全州范围内的 集水领域面临独特的挑战，面临健康的社会决定因素和在以下方面的严重差距 癌症发病率和死亡率，特别是该州的美国印第安人(AI)、黑人/非裔美国人和 农村人口。SCC有能力在其集水区和全国范围内发挥影响，因为 有战略目标的招聘和投资，利用了关键的差异化因素：1)SCC 继续投资与人工智能部落合作伙伴建立和维持健康和研究伙伴关系 在整个俄克拉何马州，目前有22个由NIH资助的项目解决人工智能癌症差异；2)SCC 继续在NCI/NCTN中处于全国领先地位，并建立了全州范围的附属网站网络，以 确保在其整个集水区获得NCI赞助的临床试验；3)SCC已发展成强大的 在其所有项目中以团队为基础的研究，在妇科、结肠和胰腺领域处于全国领先地位 癌症、癌症预防、癌症治疗、老年肿瘤学和烟草控制；以及4)SCC是 凭借其在移动卫生技术方面的全国领先地位，解决农村和农村地区的癌症负担 弱势群体。 多项NCI CCSG指标强调报告期间SCC的成长和成熟 (2017-21)。SCC成员从83人增加到120人(45%)，其中31人是外部成员 被招募来为项目增加专业知识。经同行评审的年度研究经费(DC)增长61%(1428万美元 2297万美元)，年度研究经费总额增长42%(3013万美元为4309万美元)。五年来的总人数 自上次报告所述期间(9451 454)以来，科学出版物增加了54%，其中16% 影响因子≥为10(高于7%)。强调团队科学，因此获得了139项合作资助 与上一个报告所述期间相比，方案间出版率增加了17%(从4%增加)。 在过去五年中，每年积极干预的干预机构的数量翻了一番，从20人增加到40人，每年 对干预性投资信托基金的应计利润从661(2017)增加到927(2021)--增加了40%。这一程度 由于CCSG提供的基础设施，有可能实现有影响力的增长，并 将SCC成功更新为NCI指定的癌症中心。

OVERALL: ABSTRACT Since achieving NCI designation in 2018, the Stephenson Cancer Center (SCC) at the University of Oklahoma has continued to grow and mature as an organization. The SCC’s vision to eliminate cancer in Oklahoma and beyond is advanced through its mission to provide patient-centered, research-driven, multidisciplinary cancer care to all Oklahomans. As Oklahoma’s only NCI-designated cancer center, the SCC serves a statewide catchment area that presents unique challenges with social determinants of health and high disparities in cancer incidence and mortality, especially for the state’s American Indian (AI), Black/African American, and rural populations. The SCC has the ability to be impactful in its catchment area and nationally due to strategically targeted recruitments and investments that have leveraged key differentiating factors: 1) the SCC continues to invest in creating and sustaining health and research partnerships with AI tribal partners throughout Oklahoma and currently has 22 NIH funded projects addressing AI cancer disparities; 2) the SCC continues to be a national leader in the NCI/NCTN and has established a statewide network of affiliate sites to ensure access to NCI-sponsored clinical trials throughout its catchment area; 3) the SCC has developed strong team-based research across all of its programs with national leadership in gynecologic, colon, and pancreatic cancers, cancer prevention, cancer therapeutics, gero-oncology, and tobacco control; and 4) the SCC is building upon its national leadership in mobile health technologies to address the burden on cancer in rural and vulnerable populations. Multiple NCI CCSG metrics emphasize the growth and maturation of the SCC during the reporting period (2017-21). SCC membership increased from 83 to 120 (45%), with 31 of these new members being externally recruited to add expertise to programs. Annual, peer-reviewed research funding (DC) grew 61% ($14.28M  $22.97M) and total annual research funding grew 42% ($30.13M  $43.09M). The overall five-year number of scientific publications has increased by 54% since the last reporting period (945  1,454), with 16% having an impact factor ≥10 (up from 7%). Team science has been emphasized resulting in 139 collaborative grants (36% increase) and a 17% inter-programmatic publication rate (up from 4%) over the prior reporting period. The number of annual active interventional IITs has doubled from 20 to 40 over the past five years, with annual accruals to interventional IITs increasing from 661 (2017) to 927 (2021) – a 40% increase. This degree of impactful growth has been possible due to the infrastructure made available through the CCSG and has positioned the SCC for a successful renewal as a NCI-designated cancer center.